Interventional × Epstein-Barr Virus Infections × Dermatologic × Clear all
NCT05592626 2025-07-09

START-001

Marengo Therapeutics, Inc.

Phase 1/2 Recruiting
365 enrolled
NCT01805037 2021-09-01

Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas

Northwestern University

Phase 1/2 Terminated
20 enrolled 17 charts